Printer Friendly

Articles from M2 Pharma (October 15, 2018)

1-20 out of 20 article(s)
Title Author Type Words
Acerus Closes USD 11m Term Loan Credit Facility. 456
Aimmune Therapeutics Starts Phase 2 Study with Regeneron and Sanofi of AR101 with Adjunctive Dupilumab in Peanut-Allergic Patients. 613
AIVITA Biomedical wins PMDA approval in Japan for ROOT OF CANCER Technology. 257
Alliqua BioMedical signs definitive merger agreement with Adynxx. 251
BDD Pharma names new non-executive director of the board. 229
Bristol-Myers Squibb and Compugen to evaluate safety and tolerability of combination of Opdivo and COM701. 187
Carrick Therapeutics acquires global licensing rights to develop and commercialise BTG's CT900. 187
Chugai Presents Results from Phase III Study of Satralizumab in NMOSD. 401
Dr. Reddy's Laboratories divests API manufacturing business unit in Jeedimetla, Hyderabad, India. 178
Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the US Market. 186
First Patient Dosed in Phase 2 Study of Karuna's Lead Product Candidate KarXT for the Treatment of Schizophrenia. 698
Genentech Shows Kadcyla Reduced the Risk of Disease Recurring in People with HER2-Positive Early Breast Cancer with Residual Disease After Neoadjuvant Treatment. 566
Generex Names Crisci as General Manager, Chief Compliance Officer and Corporate Counsel of its New NuGenerex Distribution Solutions Subsidiary. 279
Innovent to launch clinical trials of the combination therapy of IBI308 and IBI305 in patients with NSCLC & HCC in China. 280
MEI Pharma signs clinical collaboration with BeiGene. 150
NIH Awards Allele with Grant for the Development of Nanoantibody Therapies for Treating Sepsis. 435
The Menarini Group signs commercial agreement for Vabomere, Orbactiv and Minocin to treat infections in 68 countries. 259
Valens awarded Health Canada ACMPR License. 180
Verastem Oncology Prices USD 150m Offering of Convertible Notes. 207
X4 Pharmaceuticals Receives Orphan Drug Designation from the US FDA for X4P-001-RD for the Treatment of WHIM Syndrome. 478

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters